The phase 2 trial aimed to investigate the utility of uMRD profiling in predicting recurrence and assessing response to nadofaragene firadenovec therapy in BCG-unresponsive NMIBC patients. The primary endpoint was to determine RFS. Researchers noticed that uMRD offers the potential for tailored treatment strategies in bladder cancer trials. Urinary minimal residual disease (uMRD) […]...
ASCO-GU 2024
Coverage of ASCO-Genitourinary Cancers Symposium 2024
Jan 25
-Jan 27, 2024